![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CFAP20 |
Gene summary for CFAP20 |
![]() |
Gene information | Species | Human | Gene symbol | CFAP20 | Gene ID | 29105 |
Gene name | cilia and flagella associated protein 20 | |
Gene Alias | BUG22 | |
Cytomap | 16q21 | |
Gene Type | protein-coding | GO ID | GO:0001539 | UniProtAcc | Q9Y6A4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
29105 | CFAP20 | SYSMH3 | Human | Oral cavity | OSCC | 2.10e-15 | 4.86e-01 | 0.2442 |
29105 | CFAP20 | SYSMH4 | Human | Oral cavity | OSCC | 1.41e-06 | 2.36e-01 | 0.1226 |
29105 | CFAP20 | SYSMH5 | Human | Oral cavity | OSCC | 1.99e-02 | 1.80e-01 | 0.0647 |
29105 | CFAP20 | SYSMH6 | Human | Oral cavity | OSCC | 1.17e-07 | 3.42e-01 | 0.1275 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00328864 | Esophagus | ESCC | regulation of microtubule-based process | 134/8552 | 240/18723 | 9.44e-04 | 4.80e-03 | 134 |
GO:00328863 | Oral cavity | OSCC | regulation of microtubule-based process | 115/7305 | 240/18723 | 2.95e-03 | 1.28e-02 | 115 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CFAP20 | SNV | Missense_Mutation | c.299G>A | p.Arg100His | p.R100H | Q9Y6A4 | protein_coding | tolerated(0.15) | benign(0.052) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
CFAP20 | SNV | Missense_Mutation | rs753911484 | c.298C>T | p.Arg100Cys | p.R100C | Q9Y6A4 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CFAP20 | SNV | Missense_Mutation | rs753911484 | c.298N>T | p.Arg100Cys | p.R100C | Q9Y6A4 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
CFAP20 | SNV | Missense_Mutation | rs753911484 | c.298C>T | p.Arg100Cys | p.R100C | Q9Y6A4 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
CFAP20 | SNV | Missense_Mutation | c.523N>C | p.Asp175His | p.D175H | Q9Y6A4 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-D5-6932-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CFAP20 | SNV | Missense_Mutation | rs781222045 | c.482G>A | p.Arg161His | p.R161H | Q9Y6A4 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CFAP20 | SNV | Missense_Mutation | novel | c.305N>A | p.Arg102His | p.R102H | Q9Y6A4 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CFAP20 | SNV | Missense_Mutation | novel | c.364C>T | p.Pro122Ser | p.P122S | Q9Y6A4 | protein_coding | deleterious(0.01) | possibly_damaging(0.873) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFAP20 | SNV | Missense_Mutation | novel | c.198N>T | p.Lys66Asn | p.K66N | Q9Y6A4 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
CFAP20 | SNV | Missense_Mutation | rs761689275 | c.338G>A | p.Arg113Gln | p.R113Q | Q9Y6A4 | protein_coding | deleterious(0.04) | possibly_damaging(0.722) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |